Uncategorized
Return attribution summary for November
admin | December 6, 2019
This document is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors. This material does not constitute research.
Portfolio managers should continue to overweight lower-rated segments with greater risk compensation (OAS), while recognizing that the rally throughout the second half of 2019 has diminished near-term expectations for further tightening. After some early turbulence in November, global demand continues to put pressure on the yield curve and lend support to US dollar spread product.
Exhibit 1: Sector recommendations for first half of 2020

Note: Sector recommendations within the IG Index are based on performance expectations for the next several months on an excess return basis (total return net of commensurate UST return). The weightings serve as a proxy recommendations for how portfolio managers should position their holdings relative to the broad IG corporate bond market. Source: Bloomberg Barclays US Corporate Index
The IG market traded mostly sideways throughout November, but netted -4 bp in aggregate tightening for the month to +104 current OAS. The Index generated another +0.65% in excess return for the month (+0.25% total return), bringing the year-to-date performance over Treasuries to an impressive +5.2%, and an even more impressive aggregate total return of +14.6% for 2019.
Lower-rated credit and long-dated paper once again outperformed, and have largely dominated as 2019’s reach for yield continued into the 11th month of the year. Lead performances by sector (Exhibit 2) were in Communications (+1.11% excess return), Insurance (+0.93%), and Finance Companies (+0.94%); meanwhile the weakest performances included Utilities (+0.46%), Energy (+0.41%) and REITs (+0.41%).
Exhibit 2: Index performance by sector – November 2019

Source: Bloomberg Barclays US Corporate Index
The big returns in Telecom and Insurance were largely a function of demand for long duration spread product amidst the back-up and then recovery of the UST 10-year and 30-year in November. Health in particular was a big driver in the Insurance space, perhaps getting a boost from the big rally in CVS, generating +1.41% in excess return versus +0.93% for Life and only +0.59% in the more intermediate-focused P&C segment. FinCos once again benefited from another leg of recovery in the legacy GECC paper (2035 maturity) still classified as Financials; as well as continued tightening in the aircraft finance subgroup, which has remained among top performers for the past several quarters on reduced Boeing concerns (737 MAX) and substantially improved industry fundamentals.
Exhibit 3: Index performance by rating – November 2019

Source: Bloomberg Barclays US Corporate Index
IG supply increased +8% year-over-year in November to $110 billion, thanks in large part to the Abbvie $30 billion debt deal to fund the AGN purchase. Volume has outpaced 2018 over the past several months, helping narrow the gap on a year-to-date basis to just -3%. More impressive has been torrid pace in the High Yield primary market, which brought a massive $36 billion haul last month, versus an anemic $5 billion in November of the prior year. Aggregate HY volume is up +55% year-to-date over a relatively weak 2018, and has served to exemplify investors’ largely unimpeded appetite for credit risk throughout most of 2019. Available spread compensation between BBB and BB credit has tested historic tights in recent months.
Exhibit 4: Index performance by maturity – November 2019

Source: Bloomberg Barclays US Corporate Index
New charts identify the top and bottom performances by issuer, broken out for November (Exhibit 5) as well as the year-to-date period (Exhibit 10). At the top of the list for last month’s top excess returns were tender bonds, including ROSW ‘35s and KPN’s high coupon ‘30s, which both benefited from offers to redeem the debt at a premium. Among the other more obvious inclusions among top performers was ABBV, as the pricing of the $30 billion new issue, used to fund AGN, drove secondary spreads materially tighter from the prior month.
Exhibit 5: Top 15/ Bottom 15 excess returns by issuer

Source: Bloomberg Barclays US Corporate Index
Also, BHF 27s and 47s continued to tighten with investors reaching for yield. The bonds offer the most spread overall in the Insurance space after heavy selling in the early months of the year. BHF long bonds have been among our recommended trade ideas in recent months, see Downside risk limited in Brighthouse 30-year paper. Likewise, higher-beta TMT issuer DISCA rallied on strong earnings at the beginning of the month and continued improvement in credit fundamentals.
In the less obvious category, several Energy names were included among the top performers for the month, despite the sector falling into the bottom three returns for November. APA, HES, and DVN all turned in top performances for the month, but were not enough to offset the heavier selling in the Pipeline subgroup within Energy. EQM, ETP, MPLX and WMB were among the hardest hit index constituents over the past several weeks.
IG Corporate Bond Index year-to-date return attribution summary
Exhibit 6: Index performance by sector – year-to-date

Source: Bloomberg Barclays US Corporate Index
Exhibit 7: Index performance by rating – year-to-date

Source: Bloomberg Barclays Corporate Index
Exhibit 8: Index performance by maturity – year-to-date

Source: Bloomberg Barclays US Corporate Index
Exhibit 9: Top 20 / Bottom 20 excess returns by issuer – year-to-date

Source: Bloomberg Barclays US Corporate Index
This material is intended only for institutional investors and does not carry all of the independence and disclosure standards of retail debt research reports. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.
This message, including any attachments or links contained herein, is subject to important disclaimers, conditions, and disclosures regarding Electronic Communications, which you can find at https://portfolio-strategy.apsec.com/sancap-disclaimers-and-disclosures.
Important Disclaimers
Copyright © 2025 Santander US Capital Markets LLC and its affiliates (“SCM”). All rights reserved. SCM is a member of FINRA and SIPC. This material is intended for limited distribution to institutions only and is not publicly available. Any unauthorized use or disclosure is prohibited.
In making this material available, SCM (i) is not providing any advice to the recipient, including, without limitation, any advice as to investment, legal, accounting, tax and financial matters, (ii) is not acting as an advisor or fiduciary in respect of the recipient, (iii) is not making any predictions or projections and (iv) intends that any recipient to which SCM has provided this material is an “institutional investor” (as defined under applicable law and regulation, including FINRA Rule 4512 and that this material will not be disseminated, in whole or part, to any third party by the recipient.
The author of this material is an economist, desk strategist or trader. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM or any of its affiliates may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.
This material (i) has been prepared for information purposes only and does not constitute a solicitation or an offer to buy or sell any securities, related investments or other financial instruments, (ii) is neither research, a “research report” as commonly understood under the securities laws and regulations promulgated thereunder nor the product of a research department, (iii) or parts thereof may have been obtained from various sources, the reliability of which has not been verified and cannot be guaranteed by SCM, (iv) should not be reproduced or disclosed to any other person, without SCM’s prior consent and (v) is not intended for distribution in any jurisdiction in which its distribution would be prohibited.
In connection with this material, SCM (i) makes no representation or warranties as to the appropriateness or reliance for use in any transaction or as to the permissibility or legality of any financial instrument in any jurisdiction, (ii) believes the information in this material to be reliable, has not independently verified such information and makes no representation, express or implied, with regard to the accuracy or completeness of such information, (iii) accepts no responsibility or liability as to any reliance placed, or investment decision made, on the basis of such information by the recipient and (iv) does not undertake, and disclaims any duty to undertake, to update or to revise the information contained in this material.
Unless otherwise stated, the views, opinions, forecasts, valuations, or estimates contained in this material are those solely of the author, as of the date of publication of this material, and are subject to change without notice. The recipient of this material should make an independent evaluation of this information and make such other investigations as the recipient considers necessary (including obtaining independent financial advice), before transacting in any financial market or instrument discussed in or related to this material.
Important disclaimers for clients in the EU and UK
This publication has been prepared by Trading Desk Strategists within the Sales and Trading functions of Santander US Capital Markets LLC (“SanCap”), the US registered broker-dealer of Santander Corporate & Investment Banking. This communication is distributed in the EEA by Banco Santander S.A., a credit institution registered in Spain and authorised and regulated by the Bank of Spain and the CNMV. Any EEA recipient of this communication that would like to affect any transaction in any security or issuer discussed herein should do so with Banco Santander S.A. or any of its affiliates (together “Santander”). This communication has been distributed in the UK by Banco Santander, S.A.’s London branch, authorised by the Bank of Spain and subject to regulatory oversight on certain matters by the Financial Conduct Authority (FCA) and the Prudential Regulation Authority (PRA).
The publication is intended for exclusive use for Professional Clients and Eligible Counterparties as defined by MiFID II and is not intended for use by retail customers or for any persons or entities in any jurisdictions or country where such distribution or use would be contrary to local law or regulation.
This material is not a product of Santander´s Research Team and does not constitute independent investment research. This is a marketing communication and may contain ¨investment recommendations¨ as defined by the Market Abuse Regulation 596/2014 ("MAR"). This publication has not been prepared in accordance with legal requirements designed to promote the independence of research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. The author, date and time of the production of this publication are as indicated herein.
This publication does not constitute investment advice and may not be relied upon to form an investment decision, nor should it be construed as any offer to sell or issue or invitation to purchase, acquire or subscribe for any instruments referred herein. The publication has been prepared in good faith and based on information Santander considers reliable as of the date of publication, but Santander does not guarantee or represent, express or implied, that such information is accurate or complete. All estimates, forecasts and opinions are current as at the date of this publication and are subject to change without notice. Unless otherwise indicated, Santander does not intend to update this publication. The views and commentary in this publication may not be objective or independent of the interests of the Trading and Sales functions of Santander, who may be active participants in the markets, investments or strategies referred to herein and/or may receive compensation from investment banking and non-investment banking services from entities mentioned herein. Santander may trade as principal, make a market or hold positions in instruments (or related derivatives) and/or hold financial interest in entities discussed herein. Santander may provide market commentary or trading strategies to other clients or engage in transactions which may differ from views expressed herein. Santander may have acted upon the contents of this publication prior to you having received it.
This publication is intended for the exclusive use of the recipient and must not be reproduced, redistributed or transmitted, in whole or in part, without Santander’s consent. The recipient agrees to keep confidential at all times information contained herein.